PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
AetnaAll Plans · Coverage · Medical Policy · Psychiatry, Pain ManagementMedium impact

Ketamine for the Treatment of Depression and Other Selected Indications (CPB 0938, reviewed 2025-12-30)

Effective date
Not stated in the notice
Identified
Aug 16, 2026

Summary

Aetna considers ketamine experimental, investigational, or unproven when given intramuscularly, intranasally, intravenously, orally, or subcutaneously for acute pain, central body pain, chronic pain, neuropathic pain, depression, generalized anxiety and social anxiety disorders, post-traumatic stress disorder, alcohol and substance use disorders, suicidal ideation, post-concussion syndrome, sickle cell vaso-occlusive crises, depression-associated sleep disturbances, stress-induced maladaptive behavior, and as a diagnostic test for catatonia. Ketamine-assisted therapy for the treatment of depression is also considered experimental, investigational, or unproven. The policy lists ICD-10 codes for these indications as not covered and states that no specific HCPCS code exists for ketamine or ketamine-assisted therapy.

Get alerts when payers change rules like this one

We check Aetna and other payers every day and email you when a change matches your specialty and state.

Get Aetna alertsPolicy Monitoring is free. No card required.

What to do

Action · 4 steps
01Billing team: Do not expect coverage for ketamine or ketamine-assisted therapy when billed for the indications listed in this policy, because they are considered experimental, investigational, or unproven.
02The listed ICD-10 codes are not covered for these indications, including F32.0 through F33.9 (major depressive disorders), F43.10 through F43.12 (post-traumatic stress disorder), G89.29 (other chronic pain), and R52 (pain, unspecified).
03The related IV infusion administration codes are 96365 through 96368 and 96372.
04Esketamine (Spravato) is addressed in related policy CPB 0950.

Codes mentioned

963659636896372D57.819F06.1F07.81F10.10F19.99F20.2F32.0F33.9F40.10F40.11F41.1F43.0F43.10F43.12F43.20F43.29F43.81F43.89F43.9F51.01F51.9G89.0G89.29M79.2R45.851R52

Original notice

Ketamine for the Treatment of Depression and Other Selected Indications (CPB 0938, reviewed 2025-12-30)
aetna.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account